What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

PDF icon Download Leaflet View the patient leaflet in PDF format

Below is a text only representation of the Patient Information Leaflet. The original leaflet can be viewed using the link above.

The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PLGB 53095/0027.

HBVAXPRO 5mcg

Package leaflet: Information for the user

HBVAXPRO® 5 micrograms suspension for injection in pre-filled syringe

Hepatitis B vaccine (recombinant DNA)

Read all of this leaflet carefully before you or your child is vaccinated because it contains important information.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor, pharmacist or nurse.
  • If you or your child get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What HBVAXPRO 5 micrograms is and what it is used for
2. What you need to know before you or your child receive HBVAXPRO 5 micrograms
3. How HBVAXPRO 5 micrograms is given
4. Possible side effects
5. How to store HBVAXPRO 5 micrograms
6. Content of the pack and other information

1. What HBVAXPRO 5 micrograms is and what it is used for

This vaccine is indicated for active immunisation against hepatitis B virus infection caused by all known subtypes in individuals from birth through 15 years of age considered at risk of exposure to hepatitis B virus.

It can be expected that hepatitis D will also be prevented by immunisation with HBVAXPRO as hepatitis D does not occur in the absence of hepatitis B infection.

The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.

2. What you need to know before you or your child receive HBVAXPRO 5 micrograms

Do not use HBVAXPRO 5 micrograms

  • if you or your child is allergic to hepatitis B surface antigen or to any of the other ingredients of HBVAXPRO (see section 6.)
  • if you or your child has a severe illness with fever

Warnings and precautions

The container of this vaccine contains latex rubber. Latex rubber may cause severe allergic reactions.

Talk to your doctor, pharmacist or nurse before you or your child receive HBVAXPRO 5 micrograms.

Others vaccines and HBVAXPRO 5 micrograms

HBVAXPRO can be administered at the same time as with hepatitis B immunoglobulin, at a separate injection site.

HBVAXPRO can be used to complete a primary immunisation course or as a booster dose in subjects who have previously received another hepatitis B vaccine.

HBVAXPRO may be administered at the same time as with some other vaccines, using separate sites and syringes.

Tell your doctor, pharmacist or nurse if you or your child is taking or has recently taken any other medicines, including medicines obtained without a prescription.

Pregnancy and breast-feeding

Caution should be exercised when prescribing the vaccine to pregnant or breast-feeding women. Ask your doctor, pharmacist or nurse for advice before taking any medicine.

Driving and using machines

HBVAXPRO is expected to have no or negligible influence on the ability to drive and use machines.

HBVAXPRO 5 micrograms contains sodium: This medicinal product contains less than 1 mmol sodium (23 mg) per dose, that is to say essentially ‘sodium- free’.

3. How HBVAXPRO 5 micrograms is given

Dosage

The recommended dose for each injection (0.5 ml) is 5 micrograms for individuals from birth through 15 years of age.

A course of vaccination should include at least three injections.

Two immunisation schedules can be recommended:

  • two injections with an interval of one month followed by a third injection 6 months after the first administration (0, 1, 6 months).
  • if immunity is needed quickly: three injections with an interval of one month and a fourth dose 1 year later (0, 1, 2, 12 months).

In case of a recent exposure to the hepatitis B virus, a first dose of HBVAXPRO together with the appropriate dose of immunoglobulin can be given.

Some local vaccination schedules currently include recommendations for a booster dose. Your doctor, pharmacist or nurse will inform you if a booster dose should be given.

Method of administration

The doctor or nurse will give the vaccine as an injection into muscle. The upper side of the thigh is the preferred site for injection in neonates and infants. The upper arm muscle is the preferred site for injection in children and adolescents.

This vaccine should never be given into a blood vessel.

Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopaenia (diminution of blood platelets) or to persons at risk of haemorrhage.

If you or your child forget one dose of HBVAXPRO 5 micrograms

If you or your child miss a scheduled injection, talk to your doctor, pharmacist or nurse. Your doctor or nurse will decide when to give the missed dose.

If you or your child have any further questions on the use of this product, ask your doctor pharmacist or nurse.

4. Possible side effects

Like all medicines, this vaccine can cause side effects, although not everybody gets them.

As with other hepatitis B vaccines, in many instances, the causal relationship of side effects to the vaccine has not been established.

The most common side effects seen are injection-site reactions: soreness, redness and hardening.

Other side effects are reported very rarely:

  • Low platelet count, lymph node disease
  • Allergic reactions
  • Nervous system disorders such as pins and needles, facial paralysis, nerve inflammations including Guillain-Barre Syndrome, inflammation of the nerve of the eye that leads to impaired vision, brain inflammation, exacerbation of multiple sclerosis, multiple sclerosis, convulsions, headache, dizziness and fainting
  • Low blood pressure, blood vessel inflammation
  • Asthma-like symptoms
  • Vomiting, nausea, diarrhoea, abdominal pain
  • Skin reactions such as eczema, rash, itching, hives and skin blistering, hair loss
  • Joint pain, arthritis, muscle pain, pain in extremity
  • Fatigue, fever, vague illness, flu-like symptoms
  • Elevation of liver enzymes
  • Inflammation of the eye which causes pain and redness

In babies born very prematurely (at or before 28 weeks of gestation) longer gaps than normal between breaths may occur for 2-3 days after vaccination.

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store HBVAXPRO 5 micrograms

Keep this vaccine out of the sight and reach of children.

Do not use this vaccine after the expiry date which is stated on the label.

Store in a refrigerator (2°C - 8°C).

Do not freeze.

Store in the original package in order to protect from light.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What HBVAXPRO 5 micrograms contains

The active substance is:

Hepatitis B virus surface antigen, recombinant (HBsAg) * ................... 5 micrograms

Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.25 milligram Al+)#

* produced in Saccharomyces cerevisiae (strain 2150-2-3) yeast by recombinant DNA technology.

# Amorphous aluminium hydroxyphosphate sulfate is included in this vaccine as an adsorbant. Adsorbants are substances included in certain vaccines to acceletate improve and/or prolong the protective effects of the vaccine.

The other ingredients are sodium chloride, borax and water for injections.

What HBVAXPRO 5 micrograms looks like and contents of the pack

HBVAXPRO 5 micrograms is a suspension for injection in a syringe.

Pack sizes of 1, 10, 20 and 50 pre-filled syringes without needle or with 2 separate needles,

Pack sizes of 1 and 10 pre-filled syringes with 1 separate needle.

Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer

Marketing Authorisation Holder in Great Britain:

Merck Sharp & Dohme (UK) Limited
120 Moorgate
London
EC2M 6UR
United Kingdom

Marketing Authorisation Holder in UK (Northern Ireland):

MSD VACCINS
162 avenue Jean Jaurès
69007 Lyon
France

Manufacturer:

Merck Sharp and Dohme, B.V.
Waarderweg, 39
2031 BN Haarlem
The Netherlands

For any information about this vaccine, please contact:

Merck Sharp & Dohme (UK) Limited
Email: [email protected]

This leaflet was last revised in April 2021.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu

© Merck Sharp & Dohme (UK) Limited, 2021. All rights reserved.

PIL.HBV.PFS.5MCG.21.GB-NI.7456.CoO-Art 61-3.RCN.020300